- Current risk assessment tools may underestimate lifelong cardiovascular disease (CVD) risk in women with hypertensive disorders of pregnancy (HDP).
Why this matters
- Accurate female-specific CVD risk prediction tools needed.
- 80% of CVDs could be avoided with pharmacotherapy and lifestyle modification.
- Using the 10-year modified Framingham Risk Score (FRS), no difference in eligibility for statin treatment in women with HDP and controls.
- Using the 30-year Risk Score, 12.2% HDP vs 1.7% controls (P<.001 eligible for statin treatment.>
- Using the Lifetime Risk Score, 49.2% HDP vs 14.3% controls (P<.0001 eligible for statin treatment.>
- Prospective cohort study.
- Cohort identified from the Maternal Health Clinic (MHC) and the Pre-Eclampsia New Emerging Team (PE-NET).
- 2016 Canadian Cardiovascular Society guidelines used to estimate CVD risk and eligibility for pharmacologic treatment of lipid levels among women with recent HDP:
- Women from MHC were assessed at 6 months postpartum;
- Women from the PE-NET study were assessed at 1 year postpartum.
- Women from MHC and PE-NET with HDP (n=379) compared with controls from PE-NET (n=131).
- Funding: None disclosed.
- None of the established CVD risk predicting tools have been validated for young women.
- Women not followed prospectively until diagnosis of CVD.